Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole Medocaril vs Daptomycin in Staphylococcus Aureus Bacteremia
NCT03138733Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2018
- Primary completion
- Mar 2022
- Modality
- Reversible Covalent Inhibitors
- Countries
- 17
01
Overview
A Phase 3 trial of ceftobiprole medocaril in Staphylococcus aureus bacteremia (SAB), sponsored by Basilea Pharmaceutica. Started Aug 2018; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT03138733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138733.